

University of California Los Angeles to launch Genetic Signatures technology after successful completion of study

- **UCLA successfully completes Genetic Signatures product trial**
- **Study demonstrates GSS 3Base™ technology & products as globally impactful**
- **Trial results to be officially published by UCLA**

Sydney, Australia, 24 June 2016: Molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) is pleased to announce that the University of California, Los Angeles (UCLA) has notified the Company that a recent GSS product evaluation was successful and showed improved pathogen detection compared to traditional methods.

“We are very pleased with our study results and look forward to working with Genetic Signatures to focus on the best technologies to enhance patient care,” said Romney Humphries, PhD D(ABMM), Section Chief, Clinical Microbiology UCLA. “We will soon be sharing our results in upcoming publications highlighting the infections that can be missed with traditional methods”

Lynne Garcia, an internationally recognized expert in parasitology, commented “Genetic Signatures has consulted with leading experts to develop an assay that identifies *Blastocystis Spp* and *Dientamoeba fragilis*, both of which are potentially clinically significant pathogens. Based on advice from their panel of experts, Genetic Signatures will soon expand their assay to identify two Microsporidia, *Enterocytozoon bieneusi* and *Encephalitozoon intestinalis*. Inclusion of these pathogens will provide clinicians with valuable information to select a course of treatment and improve patient outcomes.”

“This successful trial of our rapid pathogen screening assays, represents a key milestone in the company’s commercial rollout” said Genetic Signatures’ Chief Executive Officer, John Melki PhD. “We now look forward to developing the process with UCLA that will see Genetic Signatures products adopted into routine use.”

UCLA Senior Vice Chair, Scott W. Binder MD added, “We look forward to working with Genetic Signatures as we continually pursue the best technology and believe their science has many impactful applications benefitting patient health globally.”

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Company	Media and Investor Relations
John Melki Chief Executive Officer john@geneticsignatures.com T: +61 2 9870 7580	Peter Taylor Investor Relations peter@nwrcommunications.com.au T: +61 412 036 231

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3Base™**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the **EasyScreen™** brand. Genetic Signatures' proprietary MDx **3Base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' supplies these products to major hospital and pathology laboratories undertaking infectious disease screening. The Company plans to release additional products to continue to meet the growing need for the accurate & timely diagnosis of infectious diseases.